京東健康(06618.HK)公開發售獲421.91倍認購 發售價定為70.58港元/股
格隆匯 12 月 7日丨京東健康(06618.HK)發佈公告，公司全球發售3.819億股股份，其中香港發售股份4200.9萬股，國際發售股份3.39891億股，另有15%超額配股權；發售價已釐定為每股發售股份70.58港元，每手買賣單位50股；BofA SECURITIES、海通國際及UBS為聯席保薦人，預期股份將於2020年12月8日於聯交所主板掛牌上市。
香港公開發售項下初步可供認購的香港發售股份已獲極大幅超額認購。合共接獲846,209份有效申請，認購合共約80.56億股發售股份，相當於香港公開發售項下初步可供認購的香港發售股份總數約421.91倍。國際發售項下初步提呈發售的發售股份已獲大幅超額認購，相當於國際發售項下初步可供認購發售股份總數的約31.1倍。
根據與基石投資者的基石投資協議，基石投資者認購的發售股份數目現已釐定。 Hillhouse認購1658.4萬股，Tiger Global認購3295.225萬股，Lake Bleu Prime認購1098.405萬股，中國國有企業結構調整基金認購2188.205萬股，GIC認購3844.43萬股以及貝萊德認購2746.02萬股發售股份，約佔(i)全球發售項下初步可供認購的發售股份的38.83%(假設超額配股權未獲行使)；及(ii)緊隨全球發售完成後(假設超額配股權未獲行使且不計根據首次公開發售前員工股權激勵計劃、首次公開發售後購股權計劃及首次公開發售後股份獎勵計劃將予發行的股份)公司已發行股本總額的4.74%。
按發售價每股發售股份70.58港元計算，假設超額配股權未獲行使，全球發售募集資金淨額預計約為264.57億港元。其中，約40%募集資金淨額預計在未來36至60個月將用於業務擴張；約30%募集資金淨額預計在未來24至36個月將用於研發；約20%募集資金淨額預計將用於潛在投資及收購或戰略聯盟；及約10%募集資金淨額預計將用於營運資金及一般公司用途。倘超額配股權獲悉數行使，公司將就超額配股權獲行使後擬發行的5728.5萬股發售股份收取額外募集資金淨額約39.82億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
